Orega Biotech Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $1.38M
Latest Deal Amount
  • Investors
  • 6

Orega Biotech General Information

Description

Developer of monoclonal antibodies designed to transform scientific insights in the field of tumour immunology into improved responses to cancer immunotherapies. The company's antibodies deal in therapeutic strategies in the field of cancer, focus on tumour microenvironment and also develop antibodies for modulating regulatory T cells activities in cancers, enabling doctors to facilitate improved anticancer strategies, response rates and patient survival.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • European Space, building G
  • 15 chemin du Saquin, Ecully
  • 69130 Lyon
  • France
+33 04 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Orega Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 13-May-2014 $1.38M 00.000 Completed Generating Revenue
2. Early Stage VC 01-Sep-2010 00.00 00.00 Completed Startup
1. Accelerator/Incubator 01-Mar-2010 Completed Startup
To view Orega Biotech’s complete valuation and funding history, request access »

Orega Biotech Patents

Orega Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3454863-A1 Combinations therapies for the treatment of cancer Withdrawn 10-May-2016 0000000000
US-20190151346-A1 Combinations therapies for the treatment of cancer Abandoned 10-May-2016 0000000000 0
EP-3429692-A1 Anti-cd39 antibodies Ceased 14-Mar-2016 00000000000
US-20190071514-A1 Anti-cd39 antibodies Abandoned 14-Mar-2016 00000000000 0
CA-3005986-A1 Cd39 vascular isoform targeting agents Pending 23-Nov-2015 C07K16/2896
To view Orega Biotech’s complete patent history, request access »

Orega Biotech Executive Team (5)

Name Title Board Seat Contact Info
Jeremy Bastid Ph.D Chief Executive Officer, Director General & Member of Scientific Board
Nathalie Bonnefoy Ph.D Co-Founder, Chief Scientific Officer & Member of Scientific Board
Armand Bensussan Ph.D Co-Founder & Member of Scientific Board
Jean-François Eliaou Ph.D Co-Founder
Gilles Alberici Ph.D Co-Founder, Chairman & Member of Scientific Board
To view Orega Biotech’s complete executive team members history, request access »

Orega Biotech Board Members (3)

Name Representing Role Since
Bervin Bouani Orega Biotech Board Member 000 0000
Gilles Alberici Ph.D Orega Biotech Co-Founder, Chairman & Member of Scientific Board 000 0000
Isabelle Bou Antoun Rhône-Alpes Création Board Member 000 0000
To view Orega Biotech’s complete board members history, request access »

Orega Biotech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Orega Biotech Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Inserm Transfert Venture Capital Minority 000 0000 000000 0
Kreaxi Venture Capital Minority 000 0000 000000 0
Rhône-Alpes Création Venture Capital Minority 000 0000 000000 0
Sham Corporation Minority 000 0000 000000 0
OCTALFA Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »